Thrombotic events in neonates receiving recombinant factor VIIa or fresh frozen plasma

Pediatric Blood and Cancer

Volumn 53, Issue 6, 2009, Pages 1074-1078

  Puetz, John ^a   Darling, Ginger ^a   Brabec, Petr ^b   Blatny, Jan ^c   Mathew, Prasad ^d  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASARYK UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Bleeding; Coagulopathy; Fresh frozen plasma; Neonate; rFVIIa

Indexed keywords

FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CONTINUOUS INFUSION; CRYOPRECIPITATE; DISEASE REGISTRY; FETUS; HEMOPHILIA; HUMAN; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; MEDLINE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTE TRANSFUSION; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

BLOOD COMPONENT TRANSFUSION; FACTOR VIIA; HEMORRHAGE; HUMANS; INFANT, NEWBORN; PLASMA; PREVALENCE; RECOMBINANT PROTEINS; RISK; STATISTICS AS TOPIC; THROMBOSIS;

EID: 71149109348     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22160     Document Type: Article

References (41)

1. Hedner U. Factor VIIa and its potential therapeutic use in bleeding associated pathologies. Thromb Haemost 2008;100: 557-562.
2. Abshire T, Kenet G. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia 2008;14:898-902.
3. Aledort L. Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity. J Thromb Haemost 2004;2:1700-1708. (Pubitemid 40192708)
4. Mayer S, Brun N, Begtrup K, et al. Recombinant activated Factor VII for acute intracerebral hemorrhage. N Engl J Med 2005;352: 777-785. (Pubitemid 40271172)
5. O'Connell K, Wood S, Wise R, et al. Thromboembolic adverse events after use of recombinant human coagulation Factor VIIa. JAMA 2006;295:293-298. (Pubitemid 43112957)
6. Johnson C, Snyder M,Weaver R. Effects of frozen plasma infusions on coagulation screening tests in neonates. Arch Dis Child 1982; 57:950. (Pubitemid 13170172)
7. Duncan A, Benson L, Critz A, et al. Neonatal Coagulopathy treatment with rFVIIa. Pediatr Res 2001;49:290A.
8. Chuansumrit A, Nuntnarumit P, Okascharoen C, et al. The use of recombinant activated factor VII to control bleeding in a preterm infant undergoing exploratory laparotomy. Pediatrics 2002;110: 169-171. (Pubitemid 34742658)
9. Veldman A, Fischer D,Voigt B, et al. Life Threatening hemorrhage in neonates: Management with recombinant activated factor VII. Intensive Care Med 2002;28:1636-1637. (Pubitemid 36002514)
10. Olomu N, Kulkarni R, Manco-Johnson M. Treatment of severe pulmonary hemorrhage with activated recombinant factor VII (rFVIIa) in very low birth weight infants. J Perinat 2002;22:672-674. (Pubitemid 36150231)
11. Griesen G, Rinette B. Recombinant factor VIIa in preterm neonates with prolonged prothrombin time. Blood Coagul Fibrinolysis 2003;14:117-120.
12. Girish M, Rauch R, Carbon R, et al. Refractory bleeding following major surgery of a giant sacrococcygeal teratoma in a premature infant: Successful use of recombinant factor VIIa. Eur J Pediatr 2004;163:118-119. (Pubitemid 38223397)
13. Egan J, Lammi A, SchellD, et al. Recombinant activated factor VII in paediatric cardiac surgery. Intensive Care Med 2004;30:682-685. (Pubitemid 38530106)
14. Fontaine M, Lazarchick J, Taylor S, et al. Use of recombinant factor VIIa in infants with severe coagulopathy. J Perinat 2004;24:310-311. (Pubitemid 38684577)
15. Tancabelic J, Haun S. Management of coagulopathy with recombinant factor VIIa in a neonate with echovirus type 7. Pediatr Blood Cancer 2004;43:170-176. (Pubitemid 38891166)
16. Razon Y, Erez E, Bernardo V, et al. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease. Pediatric Anesthesia 2005;15:235-240. (Pubitemid 40364750)
17. Pychynska-Pokorska M, Moll J, Krajewski W, et al. The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass. Pediatr Crit Care Med 2004;5:246-250.
18. Velik-Salchner C, Sergi C, Fries D, et al. Use of recombinant factor VIIa(NovoSeven) in combination with other coagulation products led to a thrombotic occlusion of the truncus brachiocephalicus in a neonate supported by extracorporal membrane oxygenation. Anesth Analg 2005;101:924. (Pubitemid 41208540)
19. Millar C, Stringer M, Sugarman I, et al. The use of recombinant factor VIIa for bleeding in paediatric practice. Haemophilia 2005; 11:171-174. (Pubitemid 40468066)
20. Filan P, Mills J, Clarnette T, et al. Spontaneous liver hemorrhage during laparotomy for necrotizing enterocolitis:Apotential role for recombinant factor VIIa. J Pediatr 2005;147:857-859. (Pubitemid 41774849)
21. Wittenstein B, Cho N, Ravn H, et al. Recombinant factor VII for severe bleeding during extracorporeal membrane oxygenation following open heart surgery. Pediatr Crit Care Med 2005;6:473-476. (Pubitemid 40980831)
22. Grizelj R, Vukovic J, Filipovic-Grcic B, et al. Successful use of recombinant activated FVII and aminocaproic acid in four neonates with life-threatening hemorrhage. Blood Coagul Fibrinolysis 2006; 17:413-415. (Pubitemid 43941585)
23. Cetin H, Yalaz M, Akisu M, et al. The use of recombinant activated factor VII in the treatment of massive pulmonary hemorrhage in a preterm infant. Blood Coagul Fibrinolysis 2006;17:213-216.
24. Abdullah F, Hunter C, Hargrove C, et al. Recombinant factor VIIa for the treatment of massive liver fracture in a premature infant. J Pediatr Surg 2006;41:1764-1767. (Pubitemid 44441363)
25. Hunsler C, Kribs A, Eifinger F, et al. Recombinant activated factor seven in acute life-threatening bleeding in neonates: Report on three cases and review of literature. J Perinatol 2006;26:706-713. (Pubitemid 44650190)
26. De Santiago J, Martinez-Garcia E, Giron J, et al. Prophylactic recombinant factor VIIa administration to an infant with congenital system juvenile xanthogranuloma. Pediatric Anesthesia 2006;16: 974-976. (Pubitemid 44215162)
27. Brady K, Easley R, Tobias J. Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage. Pediatric Anesthesia 2006;16:1042-1046. (Pubitemid 44401171)
28. Veldman A, Josef J, Fischer D, et al. A prospective pilot study of prophylactic treatment of preterm neonates with recombinant activated factor VII during the first 72 hours of life. Pediatr Crit Care Med 2006;7:34-39.
29. Fischer D, Schloesser R, Buxmann H, et al. Recombinant activated factor VII as a hemostatic agent in very low birth weight preterms with gastrointestinal hemorrhage and disseminated intravascular coagulation. J Pediatr Hematol Oncol 2008;30:337-342. (Pubitemid 351643454)
30. Verrijckt A, Proulx F, Mourneau S, et al. Activated recombinant factor VII for refractory bleeding during extracorporeal membrane oxygenation. J Thorac Cardiovasc Surg 2004;127:1812-1813. (Pubitemid 38725466)
31. Mitsiakos G, Papaioannou G, Giougi E, et al. Is the use of rFVIIa safe and effective in bleeding neonates? J Pediatr Hematol Oncol 2007;29:145-150.
32. Brown J, Emerick K, Brown D, et al. Recombinant factor VIIa improves coagulopathy caused by liver failure. J Pediatr Gastroenterol Nutr 2003;37:268-272. (Pubitemid 39274516)
33. Veldman A, Neuhaeuser C, Akinturek H, et al. rFVIIa in the treatment of persistent hemorrhage in pediatric patients on ECMO following surgery for congenital heart disease. Pediatric Anesthesia 2007;17:1176-1181. (Pubitemid 350059105)
34. Altuncu A, Berrak S, Blgen H, et al. Use of recombinant factor VIIa in a preterm infant with coagulopathy and subdural hematoma. J Matern Fetal Med 2007;20:627-629. (Pubitemid 47221558)
35. Agarwal H, Bennett J, Churchwell K, et al. Recombinant factor seven therapy for postoperative bleeding in neonatal and pediatric cardiac surgery. Ann Thorac Surg 2007;84:161-169. (Pubitemid 46921117)
36. Heller M, Lau W, Pazmino-Canizares J, et al. A comprehensive review of rFVIIa use in a tertiary care pediatric center. Pediatr Blood Cancer 2008;50:1013-1017.
37. Ekert H, Brizard C, Eyers R, et al. Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonany bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: A randomized, double-blind, parallel group, placebocontrolled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy. Blood Coagul Fibrinolysis 2006;17:389-395.
38. Herbertson M, Kenet G. Applicability and safety of recombinant activated factor VII to control non-haemophilia haemorrhage: Investigational experience in 265 children. Haemophilia 2008;14: 753-762. (Pubitemid 352016031)
39. Young G, Albisetti M, Bonduel M, et al. Impact of inherited thrombophilia on venous thromboembolism in children. A systematic review of meta-analysis of observational studies. Circulation 2008;118:1373-1382.
40. Ranucci M, Giuseppe I, Soro G, et al. Efficacy and safety of recombinant activated factor VII in major surgical procedures. Systematic review and meta-analysis of randomized controlled trials. Arch Surg 2008;143:296-304.
41. Spinella P, Perkins J, McLaughlin D, et al. The effect of recombinant activated factor VII on mortality in combat-related casualties with severe trauma and massive transfusion. J Trauma 2008;64:286-294. (Pubitemid 351640428)